Sanofi and partners reported positive Phase 2 results for AlphaMedix, a lead targeted‑alpha radiopharmaceutical for gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). The compound met primary endpoints for overall response rate and safety across cohorts including patients previously treated with beta‑emitter therapy. Sanofi said secondary endpoints showed benefits in progression‑free and overall survival, and the dataset will form the basis for regulatory discussions. The readout validates Orano Med’s lead 212Pb‑based platform and supports clinical advancement of alpha‑emitters in hard‑to‑treat NET populations. Sanofi plans to present more complete data at an upcoming oncology congress and to engage regulators on next steps. The result highlights the growing momentum and commercial interest in targeted alpha therapies for rare solid tumors.